For in vitro drug treatments, NB cell lines were seeded in either 96‐well, 6‐well plates or T25, T75 flasks (Corning) at densities that would reach 80‐90% confluency at the 24‐96‐h assay endpoints. Following an initial 24‐h incubation after seeding, drug treatments were made in fresh media. GSAO and PENAO were kindly provided by Prof. Philip J. Hogg (Australian Cancer Research Foundation, Centenary Cancer Research Centre, Charles Perkins Centre, USYD, NSW, Australia) and were constituted in saline (NaCl 0.9%). Vorinostat (SAHA) (#10009929, Cayman Chemical, MI) and Panobinostat (LBH589) (#13280, Cayman Chemical) were constituted in DMSO (Sigma‐Aldrich, Castle Hill, NSW, Australia). Glutathione ethyl ester (GSH‐EE) (G1404, Sigma‐Aldrich) and N‐Acetyl‐L‐Cysteine (NAC) (A9165, Sigma‐Aldrich) were constituted in Milli‐Q H2O. Cells were incubated at 37°C with 5% CO2 for 24 to 96 h, followed by various phenotypic assays.
For in vivo drug treatments, PENAO and GSAO were constituted in saline (NaCl 0.9%) prior to injection. The chemotherapy drugs; cisplatin (Hospira), vincristine (Tocris), etoposide (Sigma) and cyclophosphamide (Baxter) were diluted from their stock solution to 5% dextrose for injection. SAHA was diluted in a solution of 5% DMSO with saline (NaCl 0.9%) prior to injection.
For in vivo drug treatments, PENAO and GSAO were constituted in saline (NaCl 0.9%) prior to injection. The chemotherapy drugs; cisplatin (Hospira), vincristine (Tocris), etoposide (Sigma) and cyclophosphamide (Baxter) were diluted from their stock solution to 5% dextrose for injection. SAHA was diluted in a solution of 5% DMSO with saline (NaCl 0.9%) prior to injection.